5 Stocks Dragging In The Health Care Sector

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 14,977 as of Monday, May 6, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,675 issues advancing vs. 1,221 declining with 157 unchanged.

The Health Care sector currently sits up 0.3% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the sector include Grifols ( GRFS), down 2.36, and Express Scripts ( ESRX), down 1.04. Top gainers within the sector include UnitedHealth Group ( UNH), up 3.0%, Humana ( HUM), up 3.0%, St Jude Medical ( STJ), up 2.7% and Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. AstraZeneca ( AZN) is one of the companies pushing the Health Care sector lower today. As of noon trading, AstraZeneca is down $0.27 (-0.5%) to $51.76 on light volume Thus far, 377,254 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $51.64-$51.91 after having opened the day at $51.90 as compared to the previous trading day's close of $52.03.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $64.1 billion and is part of the drugs industry. The company has a P/E ratio of 10.3, below the S&P 500 P/E ratio of 17.7. Shares are up 10.1% year to date as of the close of trading on Friday.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full AstraZeneca Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Sanofi ( SNY) is down $1.20 (-2.2%) to $53.14 on light volume Thus far, 416,178 shares of Sanofi exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $53.11-$53.70 after having opened the day at $53.57 as compared to the previous trading day's close of $54.34.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $147.5 billion and is part of the drugs industry. The company has a P/E ratio of 29.6, above the S&P 500 P/E ratio of 17.7. Shares are up 17.4% year to date as of the close of trading on Friday.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $3.30 (-1.2%) to $262.86 on heavy volume Thus far, 969,402 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $255.88-$265.00 after having opened the day at $264.15 as compared to the previous trading day's close of $266.16.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $23.8 billion and is part of the drugs industry. The company has a P/E ratio of 36.8, above the S&P 500 P/E ratio of 17.7. Shares are up 55.6% year to date as of the close of trading on Friday.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Biogen Idec ( BIIB) is down $1.24 (-0.6%) to $217.61 on light volume Thus far, 493,580 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $216.62-$222.00 after having opened the day at $221.72 as compared to the previous trading day's close of $218.85.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $51.6 billion and is part of the drugs industry. The company has a P/E ratio of 34.5, above the S&P 500 P/E ratio of 17.7. Shares are up 49.5% year to date as of the close of trading on Friday.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Amgen ( AMGN) is down $1.20 (-1.1%) to $105.28 on light volume Thus far, 950,512 shares of Amgen exchanged hands as compared to its average daily volume of 4.9 million shares. The stock has ranged in price between $104.68-$106.13 after having opened the day at $106.08 as compared to the previous trading day's close of $106.48.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $79.1 billion and is part of the drugs industry. The company has a P/E ratio of 18.0, above the S&P 500 P/E ratio of 17.7. Shares are up 22.5% year to date as of the close of trading on Friday.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing